Dysentery medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 16: Line 16:
{| class="wikitable" border="1" style="background:FloralWhite"
{| class="wikitable" border="1" style="background:FloralWhite"
|- align="center"
|- align="center"
|'''Possible Pathogens'''
|'''Characteristics of the Patient'''
|'''Characteristics of the Patient'''
|'''Possible Pathogens'''
|'''Preferred Treatment'''
|'''Preferred Treatment'''
|'''Duration of Treatment'''
|'''Duration of Treatment'''
|- align="center"
|- align="center"
|'''Immunocompetent patient'''


| Shigella species
| Shigella species
 
|'''Immunocompetent patient'''
|'''TMP-SMZ''', 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. (if susceptible)
|'''TMP-SMZ''', 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. (if susceptible)


Line 44: Line 43:
'''Flouroquinolones'''[( '''ofloxacin''','''norfloxacin''' and '''ciprofloxacin''' for 3 days ) and ('''nalidixic acid''' for 5 days )]
'''Flouroquinolones'''[( '''ofloxacin''','''norfloxacin''' and '''ciprofloxacin''' for 3 days ) and ('''nalidixic acid''' for 5 days )]
|- align="center"
|- align="center"
|'''Immunocompromised patient'''


| Shigella species
| Shigella species
 
|'''Immunocompromised patient'''
| Same as above
| Same as above
| Same as above except that duration of antibiotics is for 7- 10 days
| Same as above except that duration of antibiotics is for 7- 10 days
|- align="center"
|- align="center"
| Non-typhi species of Salmonella
|'''Immunocompetent patient'''
|'''Immunocompetent patient'''
Not recommended routinely, but if  
Not recommended routinely, but if  
Line 66: Line 65:


*Uremia,
*Uremia,
| Non-typhi species of Salmonella
|'''TMP-SMZ''' (if susceptible) or '''fluoroquinolone'''as above, b.i.d;  
|'''TMP-SMZ''' (if susceptible) or '''fluoroquinolone'''as above, b.i.d;  


Line 74: Line 72:
| '''TMP-SMZ''' (if susceptible) or '''fluoroquinolone''' for 5 - 7 days
| '''TMP-SMZ''' (if susceptible) or '''fluoroquinolone''' for 5 - 7 days
|- align="center"
|- align="center"
|  Non-typhi species of Salmonella
|'''Immunocompromised patient'''
|'''Immunocompromised patient'''
Same as above
Same as above
|  Non-typhi species of Salmonella
| Same as above
| Same as above
| Same as above except that duration of antibiotics is for 14 days (or longer if relapsing)
| Same as above except that duration of antibiotics is for 14 days (or longer if relapsing)
|- align="center"
|- align="center"
| Campylobacter species
|'''Immunocompetent patient'''
|'''Immunocompetent patient'''
| Campylobacter species
| '''Erythromycin''' 500 mg b.i.d.
| '''Erythromycin''' 500 mg b.i.d.
| '''Erythromycin''' for 5 days
| '''Erythromycin''' for 5 days
|- align="center"
|- align="center"
| Campylobacter species
|'''Immunocompromised patient'''
|'''Immunocompromised patient'''
| Campylobacter species
| Same as above
| Same as above
| Same as above but may require prolonged treatment
| Same as above but may require prolonged treatment


|- align="center"
|- align="center"
| Enterohemorrhagic E Coli
|'''Immunocompetent patient'''
|'''Immunocompetent patient'''
'''OR'''
'''OR'''
'''Immunocompromised patient'''
'''Immunocompromised patient'''
| Enterohemorrhagic E Coli
| Avoid antimotility drugs ; role of antibiotics unclear,and administration should be avoided
| Avoid antimotility drugs ; role of antibiotics unclear,and administration should be avoided
| Avoid antimotility drugs ; role of antibiotics unclear,and administration should be avoided
| Avoid antimotility drugs ; role of antibiotics unclear,and administration should be avoided
|- align="center"
|- align="center"


| Yersina species
| '''Immunocompromised patient'''
| '''Immunocompromised patient'''


Line 106: Line 108:
''' Pseudoappendicitis syndrome'''
''' Pseudoappendicitis syndrome'''


| Yersina species
| '''TMP-SMZ''', 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. (if susceptible)
| '''TMP-SMZ''', 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. (if susceptible)



Revision as of 18:44, 3 December 2012

Dysentery Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Dysentery from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Dysentery medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Dysentery medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dysentery medical therapy

on Dysentery medical therapy

Dysentery medical therapy in the news

Blogs on Dysentery medical therapy

Directions to Hospitals Treating Dysentery

Risk calculators and risk factors for Dysentery medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Dysentery is initially managed by maintaining fluid intake using oral rehydration therapy. If this treatment cannot be adequately maintained due to vomiting or the profuseness of diarrhea, hospital admission may be required for intravenous fluid replacement. In ideal situations, no antimicrobial therapy should be administered until microbiological microscopy and culture studies have established the specific infection involved. When laboratory services are not available, it may be necessary to administer a combination of drugs, including an amoebicidal drug to kill the parasite and an antibiotic to treat any associated bacterial infection.

If shigella is suspected and it is not too severe, the doctor may recommend letting it run its course — usually less than a week. The patient will be advised to replace fluids lost from diarrhea. If the shigella is severe, the doctor may prescribe antibiotics, such as ciprofloxacin or TMP-SMX (Bactrim). However, many strains of shigella are becoming resistant to common antibiotics, and effective medications are often in short supply in developing countries. If necessary, a doctor may have to reserve antibiotics for those at highest risk for death, including young children, people over 50, and anyone suffering from dehydration or malnutrition.

Amoebic dysentery usually calls for a two-pronged attack. Treatment should start with a 10-day course of the antimicrobial drug metronidazole (Flagyl). To finish off the parasite, the doctor can prescribe a course of diloxanide furoate (available only through the Centers for Disease Control and Prevention), paromomycin (Humatin), or iodoquinol (Yodoxin).

Shown below is a table summarizing the preferred and alternative empiric treatment for Dysentery.
Possible Pathogens Characteristics of the Patient Preferred Treatment Duration of Treatment
Shigella species Immunocompetent patient TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. (if susceptible)

OR

Fuoroquinolone(e.g., 300 mg ofloxacin, 400 mg norfloxacin, or 500 mg ciprofloxacin b.i.d.) (A-I); nalidixic acid, 55 mg/kg/d (pediatric) or 1 g/d (adults)

OR

Ceftriaxone

OR

Azithromycin

TMP-SMZ for 3 days

OR

Flouroquinolones[( ofloxacin,norfloxacin and ciprofloxacin for 3 days ) and (nalidixic acid for 5 days )]

Shigella species Immunocompromised patient Same as above Same as above except that duration of antibiotics is for 7- 10 days
Non-typhi species of Salmonella Immunocompetent patient

Not recommended routinely, but if

  • Severe or patient is <6 mo or >50 y old
  • Prostheses
  • Valvular heart disease
  • Severe atherosclerosis
  • Malignancy
  • Uremia,
TMP-SMZ (if susceptible) or fluoroquinoloneas above, b.i.d;

OR

Ceftriaxone, 100 mg/kg/d in 1 or 2 divided doses

TMP-SMZ (if susceptible) or fluoroquinolone for 5 - 7 days
Non-typhi species of Salmonella Immunocompromised patient

Same as above

Same as above Same as above except that duration of antibiotics is for 14 days (or longer if relapsing)
Campylobacter species Immunocompetent patient Erythromycin 500 mg b.i.d. Erythromycin for 5 days
Campylobacter species Immunocompromised patient Same as above Same as above but may require prolonged treatment
Enterohemorrhagic E Coli Immunocompetent patient

OR Immunocompromised patient

Avoid antimotility drugs ; role of antibiotics unclear,and administration should be avoided Avoid antimotility drugs ; role of antibiotics unclear,and administration should be avoided
Yersina species Immunocompromised patient

Bacteremia

Pseudoappendicitis syndrome

TMP-SMZ, 160 and 800 mg, respectively (pediatric dose, 5 and 25 mg/kg, respectively) b.i.d. (if susceptible)

OR

ciprofloxacin 500 mg b.i.d.

OR

Doxycycline 100 mg PO b.i.d.

TMP-SMZ for 3 - 5 days

OR

Ciprofloxacin for 3 days

OR

Doxycycline for 3 days

References

Template:WH Template:WS